The Medicines Company Reports First-Quarter 2016 Business and Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Oil drops more than $2 despite new US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- Grand Canyon Education places CFO on leave amid stock trade probe
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Funds sell $44bn in semiconductors on AI concerns
- RUM Group signs $13.7 billion GPU services deal, issues warrants
Chiesi to Acquire Medicines Co.'s (MDCO) Cleviprex, Kengreal, and Rights to Argatroban
May 9, 2016 7:08 AM EDTThe Medicines Company (NASDAQ: MDCO) announced that it has entered into a definitive agreement to sell Cleviprex (clevidipine), Kengreal (cangrelor) and the Companys rights to Argatroban for Injection to Chiesi USA, Inc. and its parent company, Chiesi Farmaceutici S.p.A., for up to $792 million, consisting of $260 million in cash payable at closing, up to $480 million in sales-based milestone payments, the assumption by Chiesi of up to $50... More
Medicines Co. (MDCO) Posts Q1 Loss of $1.03/Share
May 9, 2016 7:07 AM EDTMedicines Co. (NASDAQ: MDCO) reported Q1 EPS of ($1.03), $0.14 worse than the analyst estimate of ($0.89). Revenue for the quarter came in at $50.3 million versus the consensus estimate of $48.96 million.
For earnings history and earnings-related data on Medicines Co. (MDCO) click here.
... More